Literature DB >> 10903337

Cytotoxic mAb from rheumatic carditis recognizes heart valves and laminin.

J E Galvin1, M E Hemric, K Ward, M W Cunningham.   

Abstract

Anti-streptococcal antibodies cross-reactive with N-acetyl-betaD-glucosamine (GlcNAc) and myosin are present in the sera of patients with rheumatic fever (RF). However, their role in tissue injury is not clear. In this study, we show that anti-GlcNAc/anti-myosin mAb 3.B6 from a rheumatic carditis patient was cytotoxic for human endothelial cell lines and reacted with human valvular endothelium and underlying basement membrane. Reactivity of mAb 3.B6 with the valve was inhibited by human cardiac myosin > laminin > GlcNAc. The mAb 3.B6 epitopes were localized in fragments of human cardiac myosin, including heavy meromyosin (HMM), the S1 subfragment, and two light meromyosin (LMM) peptides containing amino acid sequences KEALISSLTRGKLTYTQQ (LMM 1) and SERVQLLHSQNTSLINQK (LMM 33). A novel feature of mAb 3.B6 was its reactivity with the extracellular matrix protein laminin, which may explain its reactivity with the valve surface. A laminin A-chain peptide (HTQNT) that includes homology to LMM33 inhibited the reactivity of mAb 3.B6 with human valve. These data support the hypothesis that cross-reactive antibodies in rheumatic carditis cause injury at the endothelium and underlying matrix of the valve.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10903337      PMCID: PMC314302          DOI: 10.1172/JCI7132

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  40 in total

1.  Myosin: a link between streptococci and heart.

Authors:  K Krisher; M W Cunningham
Journal:  Science       Date:  1985-01-25       Impact factor: 47.728

2.  Effect of valvular surgery on antibody to the group A streptococcal carbohydrate.

Authors:  E M Ayoub; A Taranta; T D Bartley
Journal:  Circulation       Date:  1974-07       Impact factor: 29.690

3.  Preparation of myosin and its subfragments from rabbit skeletal muscle.

Authors:  S S Margossian; S Lowey
Journal:  Methods Enzymol       Date:  1982       Impact factor: 1.600

4.  The production and localization of laminin in cultured vascular and corneal endothelial cells.

Authors:  D Gospodarowicz; G Greenburg; J M Foidart; N Savion
Journal:  J Cell Physiol       Date:  1981-05       Impact factor: 6.384

5.  Surface structure of the human cardiac valve. A comparative study of normal and diseased valves.

Authors:  H Harasaki; H Hanano; J Tanaka; K Tokunaga; M Torisu
Journal:  J Cardiovasc Surg (Torino)       Date:  1978 May-Jun       Impact factor: 1.888

6.  Enzymatic comparisons between light chain isozymes of human cardiac myosin subfragment-1.

Authors:  L S Tobacman; R S Adelstein
Journal:  J Biol Chem       Date:  1984-09-25       Impact factor: 5.157

7.  Persistence of streptococcal group A antibody in patients with rheumatic valvular disease.

Authors:  B A Dudding; E M Ayoub
Journal:  J Exp Med       Date:  1968-11-01       Impact factor: 14.307

8.  Multiple, heart-cross-reactive epitopes of streptococcal M proteins.

Authors:  J B Dale; E H Beachey
Journal:  J Exp Med       Date:  1985-01-01       Impact factor: 14.307

9.  Epitopes of streptococcal M proteins shared with cardiac myosin.

Authors:  J B Dale; E H Beachey
Journal:  J Exp Med       Date:  1985-08-01       Impact factor: 14.307

10.  Group A streptococcal antigens cross-reactive with myocardium. Purification of heart-reactive antibody and isolation and characterization of the streptococcal antigen.

Authors:  I van de Rijn; J B Zabriskie; M McCarty
Journal:  J Exp Med       Date:  1977-08-01       Impact factor: 14.307

View more
  61 in total

Review 1.  Cardiac myosin and the TH1/TH2 paradigm in autoimmune myocarditis.

Authors:  M W Cunningham
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

Review 2.  Understanding rheumatic fever.

Authors:  Pedro Ming Azevedo; Rosa Rodrigues Pereira; Luiza Guilherme
Journal:  Rheumatol Int       Date:  2011-09-28       Impact factor: 2.631

3.  Anti-endothelial cell antibodies in rheumatic heart disease.

Authors:  V Scalzi; H Abu Hadi; C Alessandri; C Croia; V Conti; L Agati; A Angelici; V Riccieri; C Meschini; A Al-Motarreb; A Al-Ansi; G Valesini
Journal:  Clin Exp Immunol       Date:  2010-09       Impact factor: 4.330

4.  The prospect of vaccination against group A beta-hemolytic streptococci.

Authors:  Karen L Kotloff
Journal:  Curr Infect Dis Rep       Date:  2008-05       Impact factor: 3.725

Review 5.  The role of infections in autoimmune disease.

Authors:  A M Ercolini; S D Miller
Journal:  Clin Exp Immunol       Date:  2009-01       Impact factor: 4.330

Review 6.  Unresolved issues in theories of autoimmune disease using myocarditis as a framework.

Authors:  Robert Root-Bernstein; DeLisa Fairweather
Journal:  J Theor Biol       Date:  2014-12-04       Impact factor: 2.691

Review 7.  Molecular Mimicry, Autoimmunity, and Infection: The Cross-Reactive Antigens of Group A Streptococci and their Sequelae.

Authors:  Madeleine W Cunningham
Journal:  Microbiol Spectr       Date:  2019-07

8.  Chronic lymphocytic leukemia antibodies with a common stereotypic rearrangement recognize nonmuscle myosin heavy chain IIA.

Authors:  Charles C Chu; Rosa Catera; Katerina Hatzi; Xiao-Jie Yan; Lu Zhang; Xiao Bo Wang; Henry M Fales; Steven L Allen; Jonathan E Kolitz; Kanti R Rai; Nicholas Chiorazzi
Journal:  Blood       Date:  2008-09-23       Impact factor: 22.113

9.  Repeat exposure to group A streptococcal M protein exacerbates cardiac damage in a rat model of rheumatic heart disease.

Authors:  Davina Gorton; Suchandan Sikder; Natasha L Williams; Lisa Chilton; Catherine M Rush; Brenda L Govan; Madeleine W Cunningham; Natkunam Ketheesan
Journal:  Autoimmunity       Date:  2016-08-25       Impact factor: 2.815

10.  Rheumatic heart disease: 15 years of clinical and immunological follow-up.

Authors:  Roney O Sampaio; Kellen C Fae; Lea M F Demarchi; Pablo M A Pomerantzeff; Vera D Aiello; Guilherme S Spina; Ana C Tanaka; Sandra E Oshiro; Max Grinberg; Jorge Kalil; Luiza Guilherme
Journal:  Vasc Health Risk Manag       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.